IPAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:26):

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally...

Stats
本日の出来高	21 780.00
平均出来高	606 177
時価総額	35.26M
EPS	$0 ( 2024-03-21 )
次の収益日	( $-0.100 ) 2024-07-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.85
ATR14	$0.0150 (1.13%)

Insider Trading

Date	Person	Action	Amount	type
2008-12-12	Aisling Capital Ii Lp	Buy	861 826	Convertible 12% Note Due 2009
2008-12-12	Aisling Capital Ii Lp	Buy	10 412	Series D-1 Convertible Preferred Stock
2008-12-12	Aisling Capital Ii Lp	Buy	1	Warrant (right to buy)
2008-12-12	Aisling Capital Ii Lp	Buy	1	Warrant (right to buy)
2008-12-12	Aisling Capital Ii Lp	Sell	10 000	Series C-1 Convertible Preferred Stock

INSIDER POWER
0.00
Last 20 transactions
Buy: 4 917 425 \| Sell: 9 058 105

ボリューム相関

長: -0.20 (neutral)

短: 0.19 (neutral)

Signal:(47.692) Neutral

ImmunoPrecise Antibodies 相関

10 最も正の相関
CBNK	0.964
ALRS	0.959
BWB	0.957
WTBA	0.956
UTHR	0.956
KNSA	0.955
HALO	0.952
SFST	0.951
AROW	0.951
WASH	0.95

10 最も負の相関
DUOL	-0.959
SVFAU	-0.957
LGACU	-0.957
APXI	-0.956
SVFA	-0.953
SCOB	-0.952
DSEY	-0.952
ALTR	-0.951
LGAC	-0.951
NVDA	-0.951

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ImmunoPrecise Antibodies 相関 - 通貨/商品

0.73
( moderate )

0.85
( strong )

0.00
( neutral )

0.69
( moderate )

-0.74
( moderate negative )

-0.31
( neutral )

ImmunoPrecise Antibodies 財務諸表

Annual	2022
収益:	$20.67M
総利益:	$11.56M (55.95 %)
EPS:	$-1.070

FY	2022
収益:	$20.67M
総利益:	$11.56M (55.95 %)
EPS:	$-1.070

FY	2022
収益:	$19.36M
総利益:	$10.98M (56.72 %)
EPS:	$-0.850

FY	2021
収益:	$17.91M
総利益:	$11.54M (64.41 %)
EPS:	$-0.450

Financial Reports:

No articles found.

ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.